Biotech | August 11, 2021
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Innovative solutions and a deep understanding of the market makes this a unique combination
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Subscribe To Our Newsletter & Stay Updated
